Skip to content

Red cell antibody profile in Covid-19

A study of red cell antibody profile in patients of Covid-19 in a tertiary care center

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/10/028567
Enrollment
200
Registered
2020-10-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Seth GS Medical College and KEM Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Blood sample must be of covid-19 positive patient. This is mentioned on the requisition form and the RT PCR status will be doubly reconfirmed by calling up the ward. And 2) At least one of the following: i) Sample showing blood group discrepancy (Extra serum reactivity) causing difficulty in interpretation of blood groups ii) Sample showing incompatible crossmatch with at least one donor unit in saline and /or antiglobulin phase iii) Sample showing positive direct and /or indirect antiglobulin test (any of the grades weak ,1+, 2+, 3+ ,4+) Blood grouping discrepancy is defined as the situation when the results of forward and reverse blood group do not match , thus giving rise to difficulty in the interpretation of blood group.

Exclusion criteria

Exclusion criteria: 1) Sample that was found hemolysed after completion of all the prescribed tests on the sample. This will be assessed by visual inspection as per the existing SOP 2) Inadequate left over sample ( less than 1ml)

Design outcomes

Primary

MeasureTime frame
There is no intervention in the study. The expected results: samples are likely to show positive Direct antiglobulin test and presence of cold antibodiesTimepoint: At day 0: Antiglobulin test results and red cell antibody screening will be performed. They are expected to show positive results At day 4: Type of antibody (warm or cold) and identification of antibody will be performed on the same sample. At 2 months: Patients clinical profile will be assessed and will be correlated with antibody profile.

Secondary

MeasureTime frame
Antibodies are likely to be associated with severe CovidTimepoint: At 2 months: Presence of antibodies will be correlated with severity of disease

Countries

India

Contacts

Public ContactDr Swarupa Nikhil Bhagwat

Seth GS Medical College and KEM Hospital, Mumbai

swarupabhagwat@kem.edu9969044986

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026